We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+12.22%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$92.4M
Cap. Flow
+$88.5M
Cap. Flow %
24.56%
Top 10 Hldgs %
19.65%
Holding
155
New
60
Increased
18
Reduced
21
Closed
31

Top Buys

Rank Stock Value
1
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$9.64M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$6.47M
3
ALDX icon
Aldeyra Therapeutics
ALDX
+$6.31M
4
CDNA icon
CareDx
CDNA
+$6.31M
5
VRCA icon
Verrica Pharmaceuticals
VRCA
+$6.28M

Top Sells

Rank Stock Value
1
IRD
Opus Genetics
IRD
+$15.5M
2
GNPX icon
Genprex
GNPX
+$6.81M
3
ANAB icon
AnaptysBio
ANAB
+$5.62M
4
COGT icon
Cogent Biosciences
COGT
+$4.86M
5
CLDX icon
Celldex Therapeutics
CLDX
+$4.47M

Sector Composition

Rank Sector Weight
1 Healthcare 82.98%
2 Financials 2.24%
3 Consumer Staples 0.95%
4 Industrials 0.89%
5 Technology 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCRR
26
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$4.62M 1.28%
209,130
+135,139
+183% +$3.68M
FBRX icon
27
Forte Biosciences
FBRX
$1.57B
$4.61M 1.28%
+5,382
New +$4.41M
MREO
28
Mereo BioPharma
MREO
$48.8M
$4.21M 1.17%
+1,250,000
New +$4.42M
HARP
29
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$4.18M 1.16%
19,961
+9,762
+96% +$1.96M
EUCRU
30
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$4M 1.11%
400,000
– –
AVDL
31
DELISTED
Avadel Pharmaceuticals
AVDL
$3.98M 1.11%
440,589
-25,000
-5% -$202K
NAUT icon
32
Nautilus Biotechnolgy
NAUT
$113M
$3.95M 1.1%
286,383
-113,617
-28% -$1.57M
RNAM
33
DELISTED
Avidity Biosciences
RNAM
$3.9M 1.08%
+178,600
New +$4.37M
IMTX icon
34
Immatics
IMTX
$1.29B
$3.86M 1.07%
344,558
-61,112
-15% -$693K
INSM icon
35
Insmed
INSM
$28.9B
$3.75M 1.04%
110,254
-38,489
-26% -$1.47M
CTMX icon
36
CytomX Therapeutics
CTMX
$734M
$3.73M 1.04%
483,041
+209,338
+76% +$1.66M
CNST
37
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$3.71M 1.03%
158,733
+24,500
+18% +$742K
IMVT icon
38
Immunovant
IMVT
$8.21B
$3.68M 1.02%
229,622
+152,000
+196% +$4.01M
TFFP
39
DELISTED
TFF Pharmaceuticals, Inc. Common Stock
TFFP
$3.66M 1.02%
+10,788
New +$4.39M
AHACU
40
DELISTED
Alpha Healthcare Acquisition Corp Unit
AHACU
$3.44M 0.95%
275,000
– –
NBEV
41
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$3.43M 0.95%
+1,198,150
New +$3.66M
GKOS icon
42
Glaukos
GKOS
$10.1B
$3.42M 0.95%
+40,800
New +$3.59M
ARQT icon
43
Arcutis Biotherapeutics
ARQT
$3.32B
$3.3M 0.92%
113,962
+51,000
+81% +$1.59M
KALV
44
DELISTED
KalVista Pharmaceuticals
KALV
$3.29M 0.91%
+128,130
New +$3.37M
KDNY
45
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$3.2M 0.89%
205,799
– –
INFI
46
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$3.14M 0.87%
+972,327
New +$3.24M
ILMN icon
47
Illumina
ILMN
$29.3B
$3.07M 0.85%
8,224
-3,290
-29% -$1.34M
IFRX icon
48
InflaRx
IFRX
$253M
$3.02M 0.84%
+774,600
New +$3.97M
GMED icon
49
Globus Medical
GMED
$11B
$3.01M 0.84%
48,862
+17,350
+55% +$1.1M
ITCI
50
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3M 0.83%
88,326
-65,022
-42% -$2.26M
1
2
3 4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return

Altium Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Altium Capital Management held 155 positions worth $360M, up 34% from $268M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Altium Capital Management deployed $88.5M of net new capital in Q1 2021, opening 60 new positions and adding to 18 existing holdings. Its largest new stake was Biora Therapeutics, Inc. Common Stock: 6,993 shares worth $8.32M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 85% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Opus Genetics, an estimated $15.5M trimmed.

  • Altium Capital Management's largest Q1 2021 buy was Biora Therapeutics, Inc. Common Stock: 6,993 shares worth $8.32M.
  • Altium Capital Management added most to Verrica Pharmaceuticals in Q1 2021, an estimated $6.28M increase.
  • Altium Capital Management's biggest Q1 2021 reduction was Opus Genetics, cutting an estimated $15.5M.
  • Altium Capital Management fully exited AnaptysBio in Q1 2021, selling an estimated $5.62M.
  • Altium Capital Management's ten largest holdings make up 20% of its $360M portfolio in Q1 2021.
  • Altium Capital Management opened 60 new positions and closed 31 in Q1 2021.
  • Altium Capital Management's portfolio value rose 34% quarter-over-quarter to $360M.

Based on Altium Capital Management's 13F filing for Q1 2021, filed 6 May 2021.